# Manfred Ruediger

> Manfred Ruediger is a biochemist, company co-founder and former biotech CEO whose career spans Cardion, Igeneon, t2cure, LSP, Kiadis Pharma, CatalYm and Ariceum Therapeutics. He led Kiadis through its 2015 Euronext IPO and helped build CatalYm during a tenure in which it raised more than €56 million. After handing Ariceum’s CEO role to David Schilansky in August 2025, he continued as a strategic advisor and subsequently announced a focus on boards, advisory mandates and coaching.

- **Role:** Strategic Advisor at Ariceum Therapeutics; Deputy Chairman of the Supervisory Board at 4SC AG
- **Organizations:** CatalYm GmbH, Ariceum Therapeutics, 4SC AG, Thermosome GmbH, a:head bio AG, Kiadis Pharma, Life Sciences Partners (LSP), t2cure GmbH, Igeneon AG, Aphton Corporation, Cardion AG, apceth Biopharma, Technical University of Braunschweig
- **From:** Mönchengladbach, Germany
- **Education:** Diploma in Biochemistry; studies included organic chemistry and microbiology, University of Tübingen, Doctorate in Biochemistry (Dr. rer. nat.); research at the Max Planck Institute, University of Tübingen / Max Planck Institute for Biophysical Chemistry, Göttingen
- **Known for:** Led Kiadis through its 2015 Euronext IPO, which raised €34.7 million gross., CatalYm raised over €56 million during his tenure., Led apceth acquisition negotiations as its chairman ahead of the 2019 Hitachi transaction.

## Career timeline

- **1994–1998** — Academic roles at the Technical University of Braunschweig.
- **1998–2003** — Scientific and executive leadership at Cardion AG.
- **2004–2005** — CEO of Igeneon AG; the company became part of Aphton in 2005.
- **2005** — Joined the supervisory board of 4SC on 16 August.
- **2006–2009** — CEO and managing director of t2cure; public appointment announcement issued in March 2007.
- **2009–2014** — Venture Partner with Life Sciences Partners in Munich, according to the 2025 4SC CV.
- **2011–2017** — Led Kiadis; its prospectus dates his acting CEO appointment to 17 October 2011.
- **2015** — Kiadis listed on Euronext Amsterdam and Brussels on 2 July, raising €34.7 million gross.
- **2018–2021** — CEO of CatalYm according to the 4SC CV; CatalYm’s departure announcement also credits team-building since 2017.
- **2019** — As chairman of apceth Biopharma, led negotiations for its acquisition by Hitachi.
- **2021** — Left CatalYm’s CEO role effective 28 February; co-founded Ariceum in 2021.
- **2022** — Ariceum announced a €25 million Series A.
- **2023** — Ariceum extended its Series A by €22.75 million, collaborated with UCB and acquired Theragnostics.
- **2025** — David Schilansky succeeded him as Ariceum CEO on 26 August; Ruediger continued as strategic advisor.
- **2026** — Announced a shift away from operating roles toward boards, advisory mandates and coaching; joined a:head bio’s supervisory board.

## Achievements

- Led Kiadis through its 2015 Euronext IPO, which raised €34.7 million gross.
- CatalYm raised over €56 million during his tenure.
- Led apceth acquisition negotiations as its chairman ahead of the 2019 Hitachi transaction.
- Co-founded Ariceum, which announced €47.75 million in Series A financing including its 2023 extension.
- Ariceum’s UCB collaboration received the 2023 LSX Leaders European Lifestars Deal of the Year award in the under-€500 million category.

## Latest updates

- **2026-09** — LISAvienna’s September newsletter reported his appointment alongside Ralf Schmid to a:head bio AG’s supervisory board.
- **2026-08** — In a public LinkedIn post, announced that he would stop taking operating roles and focus on boards, advisory mandates and coaching; month derived from the post activity ID.
- **2025-08** — Transitioned from Ariceum CEO to strategic advisor when David Schilansky took over.

## Links

- LinkedIn: https://www.linkedin.com/in/manfred-ruediger-b034892/

---

Profile page: https://yespress.io/manfred-ruediger
Published by YesPress — https://yespress.io
Last updated: 2026-10-13